On Friday, Pacira Pharmaceuticals (PCRX) stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
XWhen you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks compares to the rest of the market.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their largest climbs. See if Pacira Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Pacira Pharmaceuticals Stock A Buy?
Pacira Pharmaceuticals stock has been trading below its 50- and 200-day moving averages. While the biotech stock is not near an ideal buy point right now, see if it goes on to form and break out of a proper consolidation.
The biotech company posted -34% EPS growth in the latest quarterly report. Sales rose 25%. Keep an eye out for the company's next round of numbers on or around Nov. 3.
Pacira Pharmaceuticals stock earns the No. 19 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab (GMAB) and Vertex Pharmaceuticals (VRTX) are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MIGHT ALSO LIKE:
MarketSmith's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
The post Pacira Pharmaceuticals Stock Shows Rising Relative Strength appeared first on Investor's Business Daily.
from Investor's Business Daily https://ift.tt/DfCORU8